Skip to content

Announcement: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Announcement: Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma

Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors

Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors

LinkedIn
X
YouTube

Presentations & Publications

ERS 2025: ePoster

09.28.2025

Download as PDF

Now we can.

Generate:Biomedicines
101 South Street, Suite 900
Somerville, MA 02143
United States

© 2026 Generate:Biomedicines

LinkedIn
X
YouTube

Privacy Policy
Terms of Use
Cookie Settings